

# OMICS Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

**For more details please visit our website:**  
**<http://omicsonline.org/Submitmanuscript.php>**

**ASAD U Khan**

**Professor and Coordinator**

**Int Biotechnology Unit AMU Aligarh 202002 India**

# Biography

Dr. Asad U Khan has received his PhD from Aligarh M University in collaboration with ICGEB, New Delhi during the period of 1998. Currently, he is working as Associate Professor in Aligarh M University. He has successfully completed his Administrative responsibilities as Editorial members of **Scientific Domain of Global Science Book, Gene, Molecular & Cell Therapy, Medical & Pharma Board, Gene Genomes & Genomics, Biochemistry Processes Biotechnology & Molecular Biology**. He /she is serving as an editorial member of several reputed journals like **PIOS ONE, *Bioinformation (Biomedical Information), Genomics proteomics and Bioinformatics (Elsevere), Asian Pacific Journal of Tropical Medicine (Elsevier), Journal of Mol. Genetic Medicine (Oxford), Journal of Industrial Research and Toxicology***. He has authored over 135 research articles, 3 books. He is a member of (1) Life member of International Society of Genomics and Evolutionary Microbiology, (2) Life member of AMI (3) Member of New York Academy of Science. He has honoured as **BOYSCAST Fellow** of DST, Government of India to work as Visiting Scientist in one of the lab in University of Napoli, Italy in 2004. He is recipient of **INSA Fellowship** of 2005 for Indian lab. He is recipient of **Young Scientist Award** and **Alembic Award** of Association of Microbiologist of India in Medical Microbiology in 2006 and 2009 respectively. In year 2010 Dr. Khan has been given “**Most Active Teachers Award of AMU**” and **DBT-CREST** award of Department of Biotechnology and **National Bioscience Award for Career Development**” of Government of India, Department of Biotechnology for the year 2012


**Characterization of some important  
resistant mutants of Class A  $\beta$ -  
lactamases**

- Beta-lactamases confer resistance to a broad range of antibiotics and inhibitors by accumulating mutations.
- The number of betalactamase and their variants are steadily increasing.
- However, the information about these betalactamase classes and their variants was scattered.
- Categorizing all these classes and associated variants along with their relevant information on one platform could be helpful to the researcher working on multidrug resistant bacteria.
- Thus, the BLAD (Betalactamase database) has been developed to provide comprehensive information on betalactamases.

## **DATABASE CONTENT**

This database includes

- Information about the sequences (nucleotide and protein)
- Resistance: It includes information about the resistance type.
- PDBS: This dataset includes information about the three dimensional structure of enzymes and their variants along with the description of physiochemical properties of bounds ligand.
- Genome: includes the information of the plasmids. These information included as type, variant, organism, resistance type, mutant, protein and nucleotide sequences with NCBI links and literature reference with the PubMed links. Cross-reference to the UniProt protein sequence database is also provided.
- The current version of BLAD holds ~4000 gene sequences which includes all classes betalactamase. Moreover, ~200 crystal structures for all types of betalactamase were also included. All the data were collected from literatures, NCBI, protein data bank (Sussman et al., 1998) and other authentic resources



**A schematic representation of architecture of BLAD database.**

# BLAD ~~β~~-Lactamase Database

A comprehensive database of widely circulated β-Lactamase

Home

Database

Resistance

PDBS


Genome

Contact Us

Feedback

## Welcome to β-Lactamase

Beta-lactamases are enzymes produced by some bacteria and are responsible for their resistance to beta-lactam antibiotics like penicillins, cephamycins, and carbapenems (ertapenem) (Cephalosporins are relatively resistant to beta-lactamase). These antibiotics have a common element in their molecular structure: a four-atom ring known as a beta-lactam. The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties.



Betalactam antibiotics and inhibitors inhibit the growth of sensitive bacteria by inactivating enzymes. Beta-lactams inhibit not just a single enzyme involved in cell wall synthesis, but a family of related enzymes aspects of cell wall synthesis. These enzymes can be detected by their covalent binding of radioactively-labeled penicillin or other beta-lactams

### Define search set:

Metallo

Non-Metallo

#### Type

Class A  
Class C  
Class D

#### Sub Type

TEM  
CTXM  
SHV  
GES  
KPC

#### Resistance Type

Any  
Inhibitor  
Antibiotic

#### Name

Any  
Clavulanate  
Sulbactum  
Tazobactum  
Penem1

Reset Search

Show Results




# BLAD $\beta$ -Lactamase Database

A comprehensive database of widely circulated  $\beta$ -Lactamase

[Home](#) [Database](#) [Resistance](#) [PDBS](#) [Genome](#) [Contact Us](#) [Feedback](#)

## Welcome to $\beta$ -Lactamase

Beta-lactamases are enzymes produced by some bacteria and are responsible for their resistance to beta-lactam antibiotics like penicillins, cephamycins, and carbapenems (ertapenem) (Cephalosporins are relatively resistant to beta-lactamase). These antibiotics have a common element in their molecular structure: a four-atom ring known as a beta-lactam. The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties.



Protein or nucleotide sequences can be retrieved from the database using GenBank accession numbers or search terms. Sequences can be downloaded, and it is possible to analyze them using the multiple sequence alignment or tree building tool integrated to the database.

Class : **A**, SubType:**SHV**, Resistance:**Inhibitor**, Name: **Clavulanate**

[Modify Search](#)

Total **3** Sequences Found

Showing 0 - 20 out of 3

| <u>Class</u> | <u>SubType</u> | <u>Variant</u> | <u>Mutation</u> | <u>Resistance Type</u> | <u>Name</u> | <u>Description</u>                  | <u>Reference</u>        |
|--------------|----------------|----------------|-----------------|------------------------|-------------|-------------------------------------|-------------------------|
| A            | SHV            | 49             | Met69Ile        | Inhibitor              | Clavulanate | <input type="button" value="View"/> | <a href="#">article</a> |
| A            | SHV            | 48             | NA              | Inhibitor              | Clavulanate | <input type="button" value="View"/> | <a href="#">article</a> |
| A            | SHV            | 72             | Lys234Arg       | Inhibitor              | Clavulanate | <input type="button" value="View"/> | <a href="#">article</a> |


# BLAD $\beta$ -Lactamase Database

A comprehensive database of widely circulated  $\beta$ -Lactamase

[Home](#) [Database](#) [Resistance](#) [PDBS](#) [Genome](#) [Contact Us](#) [Feedback](#)

## Welcome to $\beta$ -Lactamase

Beta-lactamases are enzymes produced by some bacteria and are responsible for their resistance to beta-lactam antibiotics like penicillins, cephamycins, and carbapenems (ertapenem) (Cephalosporins are relatively resistant to beta-lactamase). These antibiotics have a common element in their molecular structure: a four-atom ring known as a beta-lactam. The lactamase enzyme breaks that ring open, deactivating the molecule's antibacterial properties.



### Mutation Lys234Arg

Substitution at position 234(Lys to Arg) stabilized the conformation of the serine residue at 130 position. The O atom of serine 130 acquire the distance of 3.5Å from the O atom of serine residues at 70, which prevents the cross-linking between Ser130 and Ser70, thus decreases the susceptibility to clavulanic acid

### Important Links




<http://hwmaint.jbc.org/cgi/content/abstract/280/42/35528>

## FUTURE PROSPECTS

- This is the first time one has developed such a comprehensive database, especially for all the widely circulated  $\beta$ -lactamases which catalog, categorize, the resistance pattern about all the four different classes of  $\beta$ -lactamases identified by experimental studies.
- These informations were scattered and we have tried to bring them on a common platform.
- This database also provides information about the available three dimensional structures along with the physio-chemical properties of ligand bound within each structure.
- BLAD is equipped with highly flexible search features which includes a user-friendly browse interface and hypertext link-outs to nucleotide and protein sequence databases.
- We believe that this database will provide a very useful platform for future experimental and computational analyses of  $\beta$ -lactamases.

## Homology Modelling Process

- Template recognition
- Alignment
- Determining structurally conserved regions
- Backbone generation
- Building loops or variable regions
- Conformational search for side chains
- Refinement of structure
- Validating structures



| Plot Statistics                        |                |
|--|----------------|
| Residues                               | Percentage (%) |
| Most favoured regions [A,B,L]          | 93.1%          |
| Additional allowed regions [a,b,l,p]   | 6.5%           |
| Generously allowed regions [-a,-b-l-p] | 0.4%           |
| Disallowed regions                     | 0.0%           |
| Total                                  | 100%           |

```

SHV-1      SPQPLEQIKLSEQLSGRVGMIEMDLASGRTLTAWRADERFPMMSTFKVVLCGAVLARVDAGDEQLERKI
SHV-S130G SPQPLEQIKLSEQLSGRVGMIEMDLASGRTLTAWRADERFPMMSTFKVVLCGAVLARVDAGDEQLERKI
SHV-72     SPQPLEQIKLSEQLSGRVGMIEMDLASGRTLTAWRADERFPMMSTFKVVLCGAVLARVDAGDEQLERKI

SHV-1      HYRQQDLVDYSPVSEKHLADGMTVGELCAAITMDSNSAANLLLATVGGFAGLTAFLRQIGDNVTRLDRW
SHV-S130G HYRQQDLVDYSPVSEKHLADGMTVGELCAAITMDSNSAANLLLATVGGFAGLTAFLRQIGDNVTRLDRW
SHV-72     HYRQQDLVDYSPVSEKHLADGMTVGELCAAITMDSNSAANLLLATVGGFVGLTAFLRQIGDNVTRLDRW


SHV-1      ETELNEALPGDARDTTTPASMAATLRKLLTSQRLSARSQRQLLQWMVDDRVA GPLIRSVLPAGWFI A K T
SHV-S130G ETELNEALPGDARDTTTPASMAATLRKLLTSQRLSARSQRQLLQWMVDDRVA GPLIRSVLPAGWFI A K T
SHV-72     ETELNEALPGDARDTTTPASMAATLRKLLTSQRLSARSQRQLLQWMVDDRVA GPLIRSVLPAGWFI A L R T

SHV-1      GAGERGARGIVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR
SHV-S130G GAGERGARGIVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR
SHV-72     GAGERGARGIVALLGPNNKAERIVVIYLRDTPASMAERNQQIAGIGAALIEHWQR
  
```


Modelled structure of SHV-72 along with its Ramachandran plot and sequence alignment with its wild type.

# VALIDATION OF THE DOCKING PROTOCOL

- Docking methods are typically validated by ‘redocking’ experiments, where a known crystal complex is separated and then redocked, ensuring that the docking algorithm can reproduce the observed binding mode.
- The structure of TEM-1  $\beta$ -lactamase in complex with a designed boronic acid inhibitor (1R)-2-phenylacetamido-2-(3-carboxyphenyl) ethyl boronic acid (pdb id: 1ERO) was selected.
- Protein and ligands were separated, hydrogen atoms were added and minimized using the CHARMM force field.
- Finally the ligand was docked back into the active site of TEM-1 using GOLD.



Binding orientation of the original (green) and redocked (yellow) conformation of the ligand.





**Mutants Selected:** SHV S130G, SHV-72, TEM-30 and TEM-76

## **Library Design**

4.5 millions compounds from zinc database were scanned on the properties of the known  $\beta$ -lactamase inhibitors (Xlogp, MW, Rotatable bonds, HBD, HBA) to screen out the compounds . A total of 23,415 compounds were screened out for further analysis of their efficacies against the resistant mutants.

## **Docking-based virtual screening**

- GOLD (Genetic Optimization for Ligand Docking)
- AUTODOCK
- X-SCORE

| <b>Compounds</b>       | <b>Pubchem id</b> | <b>Fit Value</b> |
|------------------------|-------------------|------------------|
| <b>LN-1255</b>         | 25147490          | 2.94547          |
| <b>Tazobactam</b>      | 123630            | 1.99978          |
| <b>Penam-1</b>         | 21941339          | 1.99911          |
| <b>Penam-2</b>         | 21941375          | 1.96089          |
| <b>Clavulanic acid</b> | 5280980           | 1.55216          |
| <b>Sulbactam</b>       | 130313            | 1                |

**The fit values of the external test set of known  $\beta$ -lactamase inhibitors**

| <b>Compounds</b>    | <b>Fit value</b> |
|---------------------|------------------|
| <b>ZINC00959167</b> | 3.96904          |
| <b>ZINC01234548</b> | 3.93984          |
| <b>ZINC01301026</b> | 3.93677          |
| <b>ZINC14671560</b> | 3.93437          |
| <b>ZINC02775438</b> | 3.82992          |
| <b>ZINC03830398</b> | 3.67902          |
| <b>ZINC06143162</b> | 3.65642          |
| <b>ZINC01738195</b> | 3.63313          |
| <b>ZINC00627649</b> | 3.28382          |
| <b>ZINC09212678</b> | 2.99403          |

**The fit values of the test set of compounds on Hypo-1.**

| <b>Compounds</b>    | <b>Gold Fitness Score</b> |               |               |               |
|---------------------|---------------------------|---------------|---------------|---------------|
|                     | <b>SHV S130G</b>          | <b>SHV-72</b> | <b>TEM-76</b> | <b>TEM-30</b> |
| <b>ZINC00959167</b> | 62.56                     | 63.23         | 60.89         | 61.44         |
| <b>ZINC14671560</b> | 60.20                     | 60.03         | 60.25         | 62.02         |
| <b>ZINC02775438</b> | 61.95                     | 61.25         | 64.05         | 63.46         |
| <b>ZINC01301026</b> | 60.28                     | 63.16         | 61.16         | 67.99         |
| <b>ZINC01234548</b> | 63.15                     | 62.79         | 60.93         | 64.24         |

**Goldfitness score of the selected inhibitors against all the selected mutants**

| Compounds           | $\Delta G$ (Kcal/mol)<br>(autodock) | X-score | $\Delta G$ (Kcal/mol)<br>(autodock) | X-score |
|---------------------|-------------------------------------|---------|-------------------------------------|---------|
|                     | SHV S130G                           |         | SHV-72                              |         |
| <b>ZINC00959167</b> | -8.14                               | -8.23   | -6.93                               | -7.20   |
| <b>ZINC14671560</b> | -7.59                               | -7.14   | -7.02                               | -6.98   |
| <b>ZINC02775438</b> | -7.54                               | -7.85   | -7.38                               | -7.94   |
| <b>ZINC01301026</b> | -7.67                               | -7.93   | -8.54                               | -8.44   |
| <b>ZINC01234548</b> | -8.53                               | -8.24   | -6.95                               | -7.36   |

**Binding affinity obtained by autodock and x-score of the selected inhibitors against SHV S130G and SHV-72.**

| Compounds           | TEM-76                                    |         | TEM-30                                    |         |
|---------------------|---|---------|---|---------|
|                     | $\Delta G(\text{Kcal/mol})$<br>(autodock) | X-score | $\Delta G(\text{Kcal/mol})$<br>(autodock) | X-score |
| <b>ZINC00959167</b> | -6.84                                     | -6.96   | -7.56                                     | -7.20   |
| <b>ZINC14671560</b> | -6.98                                     | -7.44   | -7.73                                     | -7.18   |
| <b>ZINC02775438</b> | -7.86                                     | -7.94   | -7.46                                     | -6.94   |
| <b>ZINC01301026</b> | -7.24                                     | -6.98   | -8.42                                     | -8.23   |
| <b>ZINC01234548</b> | -6.48                                     | -7.02   | -7.94                                     | -6.97   |

**Binding affinity obtained by autodock and x-score of the selected inhibitors against TEM-76 and TEM-30.**


| <b>Compounds</b>    | <b>Residues involved</b> |   |
|---------------------|--------------------------|---|
|                     | <b>Hydrogen bond</b>     | <b>Hydrophobic interactions</b>   |
| <b>ZINC00959167</b> | K73, K234, T235          | S70, Y105, G130, T167, N170, E171, G238, E240                               |
| <b>ZINC14671560</b> | N132                     | Y105, T167, E168, N170, E171, V216, A237, G238, E240, R244, M272            |
| <b>ZINC02775438</b> | N132, N170               | S70, Y105, G130, T167, E168, E171, V216, T235                               |
| <b>ZINC01301026</b> | N132                     | S70, T167, E168, N170, E171, V216, T235, G236, A237, G238, E240, R244, M272 |
| <b>ZINC01234548</b> | N132, K234, T235         | S70, G130, N132, T167, N170, T235, A237, G238                               |

**Detail description of the amino acid residues involved in interaction of the selected inhibitors against SHV S130G**


| Compounds           | Residues involved     |   |
|---------------------|-----------------------|---|
|                     | Hydrogen bond         | Hydrophobic interactions  |
| <b>ZINC00959167</b> | N170, A237            | S70, Y105, G130, N170, V216, P219, A237, G238, M272             |
| <b>ZINC14671560</b> | No Hydrogen bond      | S70, Y105, G130, N132, P167, N170, V216, P219, G238, R244, M272 |
| <b>ZINC02775438</b> | K73, G238             | S70, Y105, G130, N132, E166, N170, V216, A237, G238, R244       |
| <b>ZINC01301026</b> | Y105                  | S70, Y105, S106, P107, G130, V216, K234, A237                   |
| <b>ZINC01234548</b> | S70, N132, N170, A237 | S70, E104, G130, P167, N170, V216, G236, R244, M272             |

**Detail description of the amino acid residues involved in interaction of the selected inhibitors against TEM-76**






**The binding mode of compound ZINC00959167  
within the active site of SHV-72**



**The binding mode of compound ZINC01234548  
within the active site of SHV-S130G**



**The binding mode of compound ZINC01301026  
within the active site of TEM-30**

Journal of Proteomics & Bioinformatics  
Related Journals

Transcriptomics: Open Access

Journal of Pharmacogenomics & Pharmacoproteomics

Journal of Data Mining in Genomics & Proteomics



For more details on Conferences Related  
Journal of Proteomics & Bioinformatics  
please visit:

<http://www.conferenceseries.com/biochemistry-meetings>

Open Access Membership with OMICS International enables academicians, research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>